Mercury Labs Reports Flat Performance in Q2, Lowest Operating Profit in 5 Quarters

Mercury Laboratories, a microcap pharmaceutical company, recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Mercury Labs has seen a flat performance in the second quarter of the fiscal year 2024-2025. However, there has been a slight improvement in the company's score, which has gone from -6 to -4 in the last three months.

The report also highlights some areas where Mercury Labs has not performed well. The company's operating profit (PBDIT) for the quarter was the lowest in the last five quarters at Rs 1.30 crore. The trend for near-term operating profit is also negative. Similarly, the operating profit margin for the quarter was the lowest in the last five quarters at 7.15%, indicating a deterioration in the company's efficiency.

The profit before tax less other income (PBT) for the quarter was also the lowest in the last five quarters at Rs 0.44 crore. The trend for near-term PBT is also negative. Additionally, the company's cash and cash equivalents for the half-yearly period were the lowest in the last six periods at Rs 2.67 crore, indicating a deterioration in short-term liquidity.

Overall, the financial results for the quarter ending September 2024 show that Mercury Laboratories has not performed well. Investors are advised to hold their stocks and monitor the company's performance closely. This news article is based on the company's financial report and does not include any external data or sources.